コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nnessee Medicaid and eligible to receive RSV immunoprophylaxis.
2 ertain endemic regions as well as failure of immunoprophylaxis.
3 s with positive maternal HBsAg under current immunoprophylaxis.
4 e mechanism of action of polyclonal anti-KEL immunoprophylaxis.
5 ays in double-KO mice despite treatment with immunoprophylaxis.
6 alloreactivity despite the use of multiagent immunoprophylaxis.
7 cgammaRs and C3 became alloimmunized despite immunoprophylaxis.
8 pecies of four MTCT pairs that broke through immunoprophylaxis.
9 m-targeted antileishmanial immunotherapy and immunoprophylaxis.
10 tants in RSV-breakthrough patients receiving immunoprophylaxis.
11 ycophenolate mofetil for posttransplantation immunoprophylaxis.
12 rapeutic approaches such as immunotherapy or immunoprophylaxis.
13 tter design strategies for immunotherapy and immunoprophylaxis.
14 will offer great clinical potential for RSV immunoprophylaxis.
15 Only 1 nonimmune respondent received immunoprophylaxis.
16 hysiologic injury led to renewed interest in immunoprophylaxis.
17 t the potential importance of the capsule in immunoprophylaxis against cholera caused by V. cholerae
19 ractive candidate for further development of immunoprophylaxis against DENV and perhaps other flavivi
20 posttransplant cyclophosphamide (Cy) as sole immunoprophylaxis against graft-versus-host disease (GVH
23 -IL-10 antibody significantly improves Flt3L immunoprophylaxis against infection mediated by Th1-type
25 alloreactivity that develops during ongoing immunoprophylaxis and identify 3 key transcriptional hal
26 st smallpox and may also be effective in the immunoprophylaxis and immunotherapy of smallpox and othe
30 ant human scFvs are potential candidates for immunoprophylaxis and therapy of flavivirus infections.
31 oresponse that occurs posttransplant despite immunoprophylaxis and to develop evidence-based strategi
32 lyclonal (CD4(+) and CD8(+)) T-cell lines as immunoprophylaxis and treatment for EBV-related lymphoma
34 Current research into the development of new immunoprophylaxis and vaccines is mainly focused on the
35 splant recipients, 24 were administered HBIg immunoprophylaxis, and 28 were administered no specific
37 antigen was chosen for study because passive immunoprophylaxis, based on gpA, has been shown to be pa
38 y more common among infants administered RSV immunoprophylaxis, compared with infants who did not rec
39 immunoprophylaxis, elective conversion from immunoprophylaxis, de novo posttransplant HBV infection,
41 owing settings: failure of prolonged passive immunoprophylaxis, elective conversion from immunoprophy
44 iform myeloablative conditioning regimen and immunoprophylaxis for graft-versus-host disease (GVHD).
46 participating in a phase 3 trial of passive immunoprophylaxis for the prevention of perinatal transm
47 of vorinostat, in combination with standard immunoprophylaxis, for prevention of GVHD in patients un
49 er clinically stable patients receiving HBIg immunoprophylaxis have detectable viral products in thei
51 ing recovery from infection, indicating that immunoprophylaxis in cats might be beneficial in helping
53 We investigated whether greater adherence to immunoprophylaxis in infants at high risk for severe RSV
54 or timing the use of future RSV vaccines and immunoprophylaxis in low- and middle-income countries.
55 emonstrates the potential of anti-HIV IgA in immunoprophylaxis in vivo, emphasizing the importance of
57 medical center of this study, high-dose HBIg immunoprophylaxis is administered at a fixed dose of 10,
59 r effective treatment, with the exception of immunoprophylaxis, is available for this infection as we
61 and its F(ab')2 derivative in an intranasal immunoprophylaxis model, we determined that Fc-mediated
62 example, we discuss the advances in passive immunoprophylaxis, most notably the shift from the recom
67 hese findings support a role for DbpA in the immunoprophylaxis of Lyme disease and suggest that DbpA
68 sulfan (3.2 mg/kg daily for 2 days) and GVHD immunoprophylaxis of mycophenolate mofetil (1 g three ti
72 Up to 3 years, no adverse sequelae of the immunoprophylaxis or clinical and ex vivo recurrent auto
74 monoclonal antibodies may provide effective immunoprophylaxis or therapy against BoNT/A intoxication
78 at high risk of HIV-1 transmission, such an immunoprophylaxis regimen could have a major impact on v
81 id neutralizing epitope of 80R, an effective immunoprophylaxis strategy with 80R should be possible i
83 ipients receiving cyclosporine-based primary immunoprophylaxis suffer higher rates of allograft rejec
85 or Disease Control and Prevention recommends immunoprophylaxis to decrease perinatal transmission.
87 action, we have now evaluated the outcome of immunoprophylaxis treatment in mice lacking Fcgamma rece
88 ecently demonstrated the ability of vectored immunoprophylaxis (VIP) to prevent intravenous transmiss
90 ion of this approach, which we call vectored immunoprophylaxis (VIP), which in mice induces lifelong
91 cond case, hepatitis B immunoglobulin (HBIG) immunoprophylaxis was administered in an attempt to prev
92 the combined group, higher adherence to RSV immunoprophylaxis was not associated with decreased asth
93 tients who received tacrolimus-based primary immunoprophylaxis were enrolled in this prospective, obs
94 5.8 years) who did not respond to postnatal immunoprophylaxis were prospectively followed for 1-22.8
95 at extremely low risk for transmission after immunoprophylaxis who are unlikely to benefit from furth
96 he American Academy of Pediatrics recommends immunoprophylaxis with a series of up to 5 injections of
98 Most patients underwent aggressive passive immunoprophylaxis with HBIg to maintain serum HBV surfac
99 However, with the introduction of passive immunoprophylaxis with hepatitis B immunoglobulin and tr
100 ections via MTCT include underutilization of immunoprophylaxis with hepatitis B vaccination and hepat
104 previously described a murine model in which immunoprophylaxis with polyclonal anti-KEL sera prevents
105 d-type and single-KO recipients treated with immunoprophylaxis, with the transfused RBCs remaining in
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。